Issue link: http://osercommunicationsgroup.uberflip.com/i/709452
C h a i n D r u g s t o r e D a i l y S u n d a y, A u g u s t 7 , 2 0 1 6 3 0 CITRON PHARMA LLC: A RISING STAR IN THE GENERIC MARKET Citron Pharma is following a high growth curve in the generic pharma mar- ket since its founding in 2013. The com- pany's growth strategy, exemplified by its early success with Duloxetine DR capsules focuses on three key factors: 1) selecting unique, high value products; 2) partnering with the best manufacturers and suppliers; and 3) leveraging a talent- ed pool of industry veterans to execute flawlessly on behalf of its customers. A Strong and Lasting Portfolio As Citron Chief Executive Officer Vimal Kavuru states, "We are not chasing the latest product coming off patent or the products with the highest IMS dollar value. We are actively developing and acquiring growth products in unique dosage forms, with limited active ingredi- ent suppliers, or undersupplied markets." Citron focuses its efforts on products with lasting value. Kavuru goes on to say, "In most cases we are not first to market, but we select products with a goal to be the last to exit." This focuses Citron's understanding of how each aspect of a product's supply chain can drive efficiency and value. One example is how the company works directly with active pharmaceutical ingredient (API) manufacturers to devel- op a reliable source of material and ensure a high degree of consistency and control. Best-In-Class Partnerships Above all, the Citron team understands the value of selecting the right partners when supplying the U.S. generic market, and that small missteps in consistency and quality can be devastating to a rapid- ly growing company. Therefore, Citron works with some of the best suppliers across the globe that share its under- standing of the market and maintain the highest stan- dards in qual- ity and cus- tomer serv- ice. Since the c o m p a n y ' s inception, building close relationships and lasting partnerships with suppliers has been a pillar of strength. Talented Industry Veterans Anchored by Founder and Chief Executive Officer Vimal Kavuru, a pharmaceutical executive and entrepre- neur with many past successes, the Citron executive team has decades of experience in the generic industry and deep relationships with customers and suppliers. The leadership team's depth in areas such as sales and marketing, business development and supply chain facilitated the company's rapid market entry in 2013, and it continues to enable Citron to build solid market shares in each product market where it competes. Although Citron's core team of industry veterans still drives much of the day to day operations, the lead- ership team is actively cultivating the next generation of industry leaders within the company. A Platform for Long Term Growth When Citron commercialized its first product in Q3 2013, it was seen as large- ly a virtual company, but today the com- pany is rapidly bringing capabilities in house – building a fully integrated phar- maceutical company. Citron recently set up a generic drug development company that has placed 30-plus ANDA filings into development and aims to file 12 to 15 products per year. In late 2015, the company also initiated construction on its first U.S. manufacturing and distribu- tion center. As the company looks to the future, it will continue acquiring and building operational capabilities that pro- vide value to its customers and add to its solid foundation of success in the gener- ic industry. Visit Citron Pharma at booth #1101. For more information, go to www.citron pharma.com, call 855.55.CITRON or email contact@citronpharma.com. LIFESCIENCE LOGISTICS BRINGS INNOVATIVE SOLUTIONS TO HEALTHCARE LifeScience Logistics, LLC (LSL), head- quartered in Dallas, Texas, offers cus- tomized 3PL solutions such as warehous- ing, distribution, order-to-cash manage- ment, quality assurance and regulatory support for the healthcare supply chain. Highly secure, cGMP-compliant facili- ties allow clients to store and distribute frozen, refrigerated and controlled room temperature products, while outsourcing as much of the process as they desire. LSL is VAWD/ISO 13485-accredited, cGMP-compliant and FDA-registered. Richard Beeny, LSL's Chief Executive Officer, says, "LSL was created expressly to provide the structure, compli- ance and service of a big box 3PL but with the agility and personalization of a small- er company. This means our clients' goals are our number one priority." LSL was founded in 2006 and has a proven track record of success, priding itself for being transparent, flexible and focused on clients' unique needs. LSL's target clients are pharma- ceutical and medical device manufacturing companies with a need for client-focused, outsourced solutions and a third-party logistics partnership. LSL recently finished construction on a 2,350 square-foot vault to house Class II controlled substances, and is cur- rently increasing the space in its Indianapolis warehouse to total more than 200,000 square feet. The expansion will include clean room capabilities and a variety of state of the art storage options. By offering innovative solutions, customized support, superior regulatory compliance and unprecedented flexibility to help achieve its clients' business goals, LSL's services present strong competi- tion in the marketplace. LSL recently launched an internal proprietary chargeback manage- ment platform (PCM), and its fully inte- grated web-based applications are com- pletely customizable, scalable, and offer clients easily configured and highly secure solutions. "Our goals for the show are to meet and network with industry professionals, increase awareness of our brand and learn about unique challenges that our clients face in the supply chain," says Beeny. For more information, visit LSL at booth #1616, go to www.lslog.com or call 888.844.9363. IMS HEALTH EXPANDS CREDENTIALS VALIDATION TO INCLUDE PHARMACY TECHNICIANS IMS Health has announced the avail- ability of version 2.0 of Medical License Monitor. This new software upgrade enables the extension of cre- dentials verification to pharmacy tech- nicians. "With this new user interface, phar- macy management is now able to moni- tor DEA, NPI and Pharmacy Technician Certification Board licenses for pharma- cy certification. This enhancement fur- ther supports the evolving role of the pharmacist and ensures that technicians are in active and good standing," said Miranda Rochol, Director of Pharmacy Solutions for IMS Health/Healthcare Data Solutions. Medical License Monitor is a tool used by human resource departments or pharmacy operations to assure that employees are legally able to fill a pre- scription. Medical License Monitor is an automated solution spe- cially designed for pharmacies as well as hospitals. MLM regu- larly performs employee background checks, licensing checks, medical exclu- sion scans and more, on a monthly and quarterly basis. HR departments, MSOs and Compliance Officers who use MLM see significant improvements in opera- tional processes, compliance with regula- tory requirements and a reduction in errors. MLM automatically investigates for: Medical Licensing Information, OIG & Medicaid Exclusions, Medicare Opt-Out, OIE LEIE Exclusions, SAM Exclusions and License Board/State Abuse Registries. T h e fines for n o n - c o m - pliance can be severe for a pharmacy. According to a new report issued by IMS Health/HDS, a single instance of not validating a DEA number may cost a pharmacy $25,000. With increased federal scrutiny, the ability to verify and validate prescriber credentials in a timely, efficient and accurate manner is not only vital for compliance but also for business. For more information, visit booth #418 or go to www.skainfo.com/solutions# pharmacy-solutions. NOVAVAX APPOINTS BOB DARIUS SENIOR VICE PRESIDENT, QUALITY OPERATIONS Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, has announced the appoint- ment of Bob Darius, Senior Vice President, Quality Operations. He will be responsible for leading the global Quality Operations of the company, including both Quality Assurance and Quality Control, as well as serving as a member of the company's senior management team. Darius joins Novavax with more than 25 years of experience in Quality Assurance, Quality Control and strategic manufacturing. As Vice President Quality Operations at GlaxoSmithKline (GSK) Biologicals, he provided over- sight of the North American and German Vaccine Manufacturing Operations for more than 10 years and most recently transitioned to Head Quality Advocacy Liaison. Darius also held positions of increasing responsibility at the Food and Drug Administration, Center for Biologics Evaluation and Research, where he was a Senior Reviewer and Inspector, Advisor to the Deputy Center Director, Medicine, on counter-bioterror- ism products. He earned a Bachelor of Science degree in Biology from George Mason University and completed gradu- ate work in biotechnology at Johns Hopkins University. For more information, go to www.novavax.com.